Author reply

Willem Jan van Weelden^{1

2}, Philine B Birkendahl¹, Roy I Lalisang^{3

4}, Joanna Inthout⁵, Roy F P M Kruitwagen^{4

6}, Andrea Romano⁴, Johanna M A Pijnenborg¹

Affiliations

¹ Department of Obstetrics and Gynaecology, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
² Department of Obstetrics and Gynaecology, Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands.
³ Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands.
⁴ GROW-School of Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands.
⁵ Section Biostatistics, Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
⁶ Department of Obstetrics and Gynaecology, Maastricht University Medical Centre+, Maastricht, The Netherlands.

Willem Jan van Weelden et al. BJOG. 2024 Feb.

. 2024 Feb;131(3):382-383.

doi: 10.1111/1471-0528.17676. Epub 2023 Oct 9.

Willem Jan van Weelden^{1

2}, Philine B Birkendahl¹, Roy I Lalisang^{3

4}, Joanna Inthout⁵, Roy F P M Kruitwagen^{4

6}, Andrea Romano⁴, Johanna M A Pijnenborg¹

¹ Department of Obstetrics and Gynaecology, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
² Department of Obstetrics and Gynaecology, Canisius Wilhelmina Ziekenhuis, Nijmegen, The Netherlands.
³ Division of Medical Oncology, Department of Internal Medicine, Maastricht University Medical Centre+, Maastricht, The Netherlands.
⁴ GROW-School of Oncology and Developmental Biology, Maastricht University Medical Centre+, Maastricht, The Netherlands.
⁵ Section Biostatistics, Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Centre, Nijmegen, The Netherlands.
⁶ Department of Obstetrics and Gynaecology, Maastricht University Medical Centre+, Maastricht, The Netherlands.

No abstract available

References

1. Qi Y, Zhang J., Questions remain on progestin effectiveness for advanced and recurrent endometrial cancer. BJOG. 2023. https://doi.org/10.1111/1471-0528.17582
1. van Weelden WJ, Birkendahl PB, Lalisang RI, IntHout J, Kruitwagen RFPM, Romano A, et al. The effect of progestin therapy in advanced and recurrent endometrial cancer: a systematic review and meta-analysis. BJOG. 2023;130(2):143-152.
1. van Weelden WJ, Lalisang RI, Bulten J, Lindemann K, van Beekhuizen HJ, Trum H, et al. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer. Am J Obstet Gynecol. 2021;225(4):407.e1-407.e16.
1. Sieuwerts AM, Inda MA, Smid M, van Ooijen H, van de Stolpe A, Martens JWM, et al. ER and PI3K pathway activity in primary ER positive breast cancer is associated with progression-free survival of metastatic patients under first-line tamoxifen. Cancers (Basel). 2020;12(4):802.
1. Makker V, Colombo N, Casado Herráez A, Santin AD, Colomba E, Miller DS, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer. N Engl J Med. 2022;386(5):437-448.